APR, the Korean owner of Medicube, reported Q2 2026 revenue of KRW 768bn (€470m), up +134% year-on-year. Operating profit reached KRW 191bn (€117m), up +135%, with the margin unchanged at 24.8%.
Cosmetics and beauty reached KRW 648bn (€397m), up +186%, and now account for 85% of sales. Growth was driven by a mix regional, channel and category expansion, including Medicube’s Collagen Glow Sunscreen, which has passed 400,000 units in cumulative sales. Beauty devices reached KRW 112bn (€69m), up +24%, or 15% of sales. Growth is still there, helped by global demand and the launch of Booster Glow, but this confirms Medicube is at core a skincare brand using devices as an acquisition engine, not a device company with skincare attached.
When looking at geographical performance, North America reached KRW 376bn (€230m), up +265%, and now represents 49% of sales. Business in the US has been driven by continued online growth with Medicube becoming the top selling skincare brand on Amazon in Q2 2026 for the first time, ahead of CeraVe and La Roche-Posay, according to data from Pattern, the leading e-commerce brand accelerator. But the brand is also successfully expanding offline through Target, Walmart and Nordstrom. Sales in Europe reached KRW 145bn (€89m), up +380%, or 19% of total sales, driven by online penetration across five main markets. Results in APAC were however more contrasted with Korea falling -14.5% to KRW 63bn (€39m) translating to 8% of revenues, as APR rationalized non-core activities in its domestic market. The rest of Asia grew +14.5% to KRW 121bn (€74m), supported by stable demand.
